Journal Article

Improving outcomes in adults with epilepsy and intellectual disability (EpAID) using a nurse-led intervention: study protocol for a cluster randomised controlled trial

Irvine, Fiona, Pullen, Angela, Donaldson, Cam, Mander, Adrian, Gilbert, Nakita, Smith, Christopher, Murphy, Caroline, Kelly, Joanna, Ring, Howard, Wason, James, Rowe, Simon, Pennington, Mark, Platt, Adam, Redley, Marcus, Jones, Elizabeth, Hook, Roxanne

2016

Overview

Background In adults with intellectual disability (ID) and epilepsy there are suggestions that improvements in management may follow introduction of epilepsy nurse-led care. However, this has not been tested in a definitive clinical trial and results cannot be generalised from general population studies as epilepsy tends to be more severe and to involve additional clinical comorbidities in adults with ID. This trial investigates whether nurses with expertise in epilepsy and ID, working proactively to a clinically defined role, can improve clinical and quality of life outcomes in the management of epilepsy within this population, compared to treatment as usual. The trial also aims to establish whether any perceived benefits represent good value for money. Methods/design The EpAID clinical trial is a two-arm cluster randomised controlled trial of nurse-led epilepsy management versus treatment as usual. This trial aims to obtain follow-up data from 320 participants with ID and drug-resistant epilepsy. Participants are randomly assigned either to a ‘treatment as usual’ control or a ‘defined epilepsy nurse role’ active arm, according to the cluster site at which they are treated. The active intervention utilises the recently developed Learning Disability Epilepsy Specialist Nurse Competency Framework for adults with ID. Participants undergo 4 weeks of baseline data collection, followed by a minimum of 20 weeks intervention (novel treatment or treatment as usual), followed by 4 weeks of follow-up data collection. The primary outcome is seizure severity, including associated injuries and the level of distress manifest by the patient in the preceding 4 weeks. Secondary outcomes include cost-utility analysis, carer strain, seizure frequency and side effects. Descriptive measures include demographic and clinical descriptors of participants and clinical services in which they receive their epilepsy management. Qualitative study of clinical interactions and semi-structured interviews with clinicians and participants’ carers are also undertaken. Discussion The EpAID clinical trial is the first cluster randomised controlled trial to test possible benefits of a nurse-led intervention in adults with epilepsy and ID. This research will have important implications for ID and epilepsy services. The challenges of undertaking such a trial in this population, and the approaches to meeting these are discussed. Trial registration International Standard Randomised Controlled Trial Number: ISRCTN96895428 version 1.1. Registered on 26 March 2013.

• Publisher: BioMed Central,BioMed Central Ltd,Springer Nature B.V
• Subject: Adult / Analysis / Biomedicine / Care and treatment / Clinical Protocols / Clinical trials / Convulsions & seizures / Costs / Data Collection / Diagnosis / Epilepsy / Epilepsy - therapy / Families & family life / Health Sciences / Hospitals / Humans / Intellectual disabilities / Intellectual Disability - therapy / Intervention / Learning disabilities / Medical care / Medicine / Medicine & Public Health / Mental retardation / Morbidity / Nurses / Outcome Assessment, Health Care / Patient outcomes / Practice / Qualitative Research / Quality management / Quality of life / Research Design / Sample Size / Statistics for Life Sciences / Study Protocol